Back to Main

Faculty Detail    
Senior Vice President and Dean
Campus Address FOT 1203
Phone  (20-5) -111
Other websites

Medical School  Johns Hopkins University S.O.M.    1986  MD 
Graduate  Johns Hopkins Hospital    1987  Surgical Internship 
Residency  Johns Hopkins Hospital    1993  General Surgery Residency 
Fellowship  Johns Hopkins Hospital    1994  MD 

Faculty Appointment(s)
Appointment Type Department Division Rank
Primary    Surgery Chair Office
Primary    Surgery - Gen Surg Gastrointestinal Section
Secondary    Med - Preventive Medicine
Primary  Surgery   Surgery Chair Office Professor
Secondary  Medicine  Med - Preventive Medicine Professor
Center  Comprehensive Cancer Center  Comprehensive Cancer Center Professor
Center  General Clinical Research Center  Minority Health & Research Center Professor

Graduate Biomedical Sciences Affiliations
Chair of Division 

Biographical Sketch 
Selwyn M. Vickers, M.D., became senior vice president for Medicine and dean of the School of Medicine at UAB on Oct. 15, 2013. Dr. Vickers, a member of the Institute of Medicine, is a world-renowned surgeon, pancreatic cancer researcher, pioneer in health disparities research and a native of Alabama. As dean, Dr. Vickers leads the medical schoolís main campus in Birmingham and the regional campuses in Montgomery, Huntsville and Tuscaloosa. He also is part of UAB Medicineís joint operational leadership (JOL) team with UAB Health System Chief Executive Officer Will Ferniany, Ph.D., and James Bonner, M.D., president of the University of Alabama Health Services Foundation, the School of Medicine faculty-physician practice group. The JOL steers operations and finances for all UAB Hospital and ambulatory medical services, including The Kirklin Clinic of UAB Hospital and the UAB Callahan Eye Hospital. Dr. Vickers continues to see patients and conduct research. His major research interests include gene therapy as an application in the treatment of pancreatobiliary tumors, the role of growth factors and receptors in the oncogenesis of pancreatic cancer, the implications of FAS expressions and Tamoxifen in the growth and treatment of cholangiocarcinoma, assessment of clinical outcomes in the surgical treatment of pancreatobiliary tumors and the role of death receptors in the treatment of pancreatic cancer. While at the University of Minnesota, Dr. Vickersí lab was instrumental in the development of an injectable cancer drug, Minnelide, which entered phase 1 testing in September 2013. Dr. Vickers has a financial interest in the pharmaceutical company licensed to develop the drug, Minneamrita Therapeutics LLC. With Donald Buchsbaum, Ph.D., Dr. Vickers is co-principal investigator for the UAB Comprehensive Cancer Centerís Specialized Program of Research Excellence (SPORE) in Pancreatic Cancer. With James Shikany, Ph.D., he is co-principal investigator of a $13.5 million grant to create the National Transdisciplinary Collaborative Center for African-American Menís Health. The NTCC is a collaborative effort with 100 Black Men of America Inc., the National USA Foundation Inc. and the National Football League to create community partnerships to design, deliver and evaluate interventions targeting the four most significant causes of death and disease across the lifespan of African-American men and boys: unintentional and violence-related injury, cardiovascular disease, cancer and stroke.